Bliss Gvs Pharma Limited

Valuation at PE 40.45 has already captured 193.54% annual returns — verify whether forward earnings growth can sustain this multiple

Operating margin range of 9.47% to 26.76% across recent quarters signals exposure to input costs, demand cycles, or product mix volatility — verify root causes

Indian pharmaceuticals face regulatory pricing pressure (NPPA) and generic competition — verify company's cost structure and product defensibility

Public shareholding (47.45%) exceeds promoter shareholding (35.01%) — verify governance safeguards and related-party transaction oversight

Operating margins improved from 9.47% (Sep 2025) to 26.76% (Jun 2026), suggesting operational efficiency gains if sustained

Regular dividend payouts across recent quarters indicate strong and consistent cash generation

EPS growth from ₹1.76 to ₹4.73 over recent periods shows profit acceleration — verify sustainability of this growth rate

India's pharmaceutical market grows with healthcare consumption and export opportunities — verify company's exposure to high-growth segments and regulated export markets